BioSpace News Archive

Endologix, Inc. (the “Company”) (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the fourth quarter ended December 31, 2018 is expected to be approximately $34 million.

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited revenues for the fourth quarter and full year ended December 31, 2018.

Company achieved its latest full-year 2018 guidance; will report Q4 2018 results on January 31, 2019

For fiscal 2018, total preliminary, unaudited revenue is expected to exceed $1.025 billion, an increase of more than 42% over 2017.

Arrowhead intends to proceed with AROAPOC31001, a Phase 1 single and multiple dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of ARO-APOC3 in adult healthy volunteers, hypertriglyceridemic patients, and patients with familial chylomicronemia syndrome

These initial data show the potential for the vast majority of patients to remain treatment free for at least 1 year

[07-January-2019] AUSTIN, Texas , Jan. 7, 2019 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects its revenues in the fourth quarter of 2018 to be approximately $81 million and to exceed $315 million for the full- year ended 2018, near the top of the previously communicated guidance range of $310 to $316 million . Select fourth quarter highlights include

A novel S1P1 modulator for the treatment of inflammatory bowel disease

The ADA Finds Colgate® Optic White® Advanced Sparkling White® Toothpaste Safe and Effective to Whiten Teeth - Going Beyond Surface Stains, to Deeply Whiten, Unlike Ordinary Toothpaste.

First Human dMAb Study Will Target Zika Infection